The Great Dane Structural Overload Profile: Growth Kinetic Weights, Chronic Osteoarthritis, and Bypassing Carprofen Clearance Thresholds

Owner jogging alongside healthy fawn Great Dane dog off-leash with restored mobility and quality of life outcomes from VetsGrade's cannabinoid pharmaceutical-sparing protocol

Will Scott |

Great Dane structural overload profile growth kinetic weights chronic osteoarthritis and bypassing carprofen clearance thresholds

The Great Dane Structural Overload Profile: Growth Kinetic Weights, Chronic Osteoarthritis, and Bypassing Carprofen Clearance Thresholds

Skeletal development in giant-breed canines introduces extreme mechanical variables that fundamentally alter the structural baseline of mammalian joint physics. The absolute physical mass of a mature Great Dane requires a massive orthopedic framework capable of absorbing immense downward gravitational strain while supporting significant muscular leverage. To achieve this impressive scale, the breed undergoes a hyper-accelerated growth curve during its initial developmental years. This rapid physical expansion, however, leaves the animal with a structural vulnerability. The massive weight accumulation routinely outpaces the structural density of immature cartilage and bone tissues, making the occurrence of progressive orthopedic breakdown a virtual guarantee as these giant canines cross into their adult and senior years.

The clinical management of an aging Great Dane is rarely limited to single joints; rather, it centers on the pharmaceutical control of widespread osteoarthritic joint space collapse across multiple heavy-load segments. Because of their immense physical weight, these dogs experience accelerated cartilage matrix degradation that quickly overwhelms traditional structural support networks. Once mobility begins to fail, conventional veterinary care protocols rely heavily on continuous, maximum-dose protocols of non-steroidal anti-inflammatory drugs to suppress non-stop joint pain. While this conventional approach can provide short-term relief, delivering large daily milligram volumes to a giant-breed patient pushes the liver's metabolic networks to their absolute physical limits. To establish a sustainable care plan that protects both the structural joints and the internal organs of a declining giant breed, formulators must look past conventional monotherapy and exploit alternative, low-toxicity peripheral receptor networks.

Harlequin Great Dane adult dog standing protectively over Great Dane puppy on sandy beach with ocean background illustrating one-hundred-fold birth weight growth kinetics within eighteen months and resulting coxofemoral laxity osteochondritis dissecans and elbow incongruity in giant-breed articular cartilage erosion

Developmental Growth Curves and Giant-Breed Articular Cartilage Erosion

Analyzing the unique dynamics of giant-breed developmental growth reveals a major mismatch in the timing of bone and cartilage maturation. Great Danes experience an extraordinarily accelerated skeletal expansion during their first eighteen months of life, increasing their birth weight by up to one hundred-fold within this brief window. This rapid growth phase places immense physical stress on the immature skeletal framework, where the development of dense cortical bone often lags behind the animal's rapid mass accumulation. This developmental imbalance frequently leads to structural irregularities like coxofemoral laxity, osteochondritis dissecans, and severe elbow incongruity.[2]

Once the skeletal frame reaches maturity, these structural irregularities create permanent mechanical issues across the articulating joint spaces. In a healthy giant-breed joint, weight is distributed across a smooth, protective layer of hyaline cartilage, a specialized tissue matrix composed of chondrocytes embedded within a dense web of type two collagen fibers and moisture-retaining proteoglycans. This dense matrix behaves as a high-utility shock absorber, using its structural elasticity to cushion subchondral bone layers from repetitive impact forces during movement. In a dysplastic or mechanically misaligned Great Dane, this protective cushion faces continuous structural degradation.[6]

As the animal walks, the abnormal physical alignment shifts the entire mechanical load onto narrow, non-optimized sections of the joint surface, generating intense physical shear forces that tear at the delicate hyaline layer. This constant scraping kills resident chondrocytes and triggers an immediate release of destructive matrix metalloproteinases directly into the surrounding synovial fluid. These destructive enzymes break down the type two collagen web and strip the moisture-retaining proteoglycans from the joint space, causing the cartilage cushion to dry out, crack, and erode over time. The body attempts to stabilize this structural failure by building irregular, sharp bony deposits called osteophytes around the joint margins, leading to chronic, severe osteoarthritis that permanently limits the animal's mobility.[6]

The giant-breed liability: Great Danes increase their birth weight by up to one hundred-fold within their first eighteen months of life. This hyper-accelerated growth routinely outpaces the structural density of immature cartilage and bone, making progressive orthopedic breakdown a virtual guarantee as these animals enter their adult years.

The Hepatic Clearance Threshold of High-Dose NSAID Maintenance

To manage the pain driven by widespread osteophyte formation and joint space collapse, conventional veterinary medicine relies almost exclusively on continuous, maximum-dose protocols of non-steroidal anti-inflammatory drugs like carprofen or meloxicam. These traditional pharmaceuticals work by binding to and blocking the inducible cyclooxygenase-two enzyme, halting the production of the inflammatory prostaglandins that drive swelling and joint pain. While this enzymatic block is highly efficient at reducing short-term pain, its continuous utilization in a giant-breed canine introduces significant metabolic liabilities due to the massive absolute milligram volume required to treat a dog of such immense scale.

The primary clearing pathway for lipophilic anti-inflammatory drugs depends entirely on the processing power of the canine liver, specifically utilizing phase one oxidation driven by the cytochrome P450 superfamily of enzymes.[20] Inside the canine liver cells, a specific subfamily of these metabolic proteins, known as the canine-specific CYP2C21 isoenzyme, bears the primary responsibility for binding, breaking down, and clearing circulating NSAID molecules from the blood.[20] Because a Great Dane can easily weigh between sixty and ninety kilograms, the absolute daily milligram payload required to maintain a therapeutic drug concentration is exceptionally high, forcing the liver's enzymatic networks to operate under maximum, non-stop demand.

Over months of uninterrupted high-dose pharmaceutical use, this massive chemical influx can hit the liver's saturation threshold, driving the local CYP2C21 enzymes into a state of chronic metabolic exhaustion. As the liver's clearing velocity slows down, standard daily doses of the medication begin to linger in the system longer than expected, extending the biological half-life of the drug and allowing active chemical compounds to accumulate in the bloodstream.[3] This systemic backup places measurable physical stress on the surrounding liver cells, a strain that is clearly reflected in routine veterinary blood work by a sharp, progressive rise in serum Alkaline Phosphatase and Alanine Aminotransferase levels.[10] If left unmanaged, this enzymatic overload can progress from subclinical liver irritation to acute hepatotoxicity or permanent hepatic lipidosis, creating a dangerous situation where the medication used to preserve mobility actively threatens the animal's internal organ health.[4]

Diverting the Cannabinoid Payload down the Intestinal Lymphatic System

To completely bypass this intense first-pass clearance and reduce the daily pharmaceutical burden on the liver, veterinary formulation science must manipulate how active therapeutic compounds enter the body. When a standard oral supplement or isolated cannabinoid fluid is swallowed by a dog, the molecules typically face immediate absorption into the capillaries of the portal venous system. The portal vein acts as a direct highway that carries blood from the digestive tract straight into the liver, exposing the entire absorbed dose to immediate first-pass hepatic metabolism before it can ever enter general circulation.[5] For highly clearable substances like cannabidiol, this direct liver filter can destroy up to eighty-five percent of the ingested milligram volume, requiring clinicians to use massive oral doses that can increase liver strain.[1][15]

To bypass this intense first-pass clearance and maximize systemic access, a high-utility formulation must use a long-chain triglyceride fat matrix composed of fatty acid chains containing fourteen or more carbon atoms.[23] Long-chain triglycerides are found in rich concentrations within natural plant fats like cold-pressed hemp seed oil and specific unsaturated botanical lipid matrices. When these large, intensely hydrophobic fats are processed within the small intestine, pancreatic lipases break them down into free long-chain fatty acids, which cross the enterocyte membrane smoothly via passive diffusion. Once inside the cell, these large components cannot dissolve into the water-rich cytoplasm; instead, they are immediately guided into the smooth endoplasmic reticulum, where they are rebuilt into new triglycerides and wrapped inside specialized lipoprotein transport vehicles known as chylomicrons.[16]

Chylomicrons consist of a dense core of re-esterified long-chain triglycerides and cholesterol esters, wrapped cleanly in a protective outer shell of hydrophilic phospholipids and specific structural proteins called apolipoproteins, primarily apolipoprotein B-48.[11] When a solventless rosin extract is delivered within a long-chain triglyceride fat matrix, the lipophilic cannabinoid molecules dissolve naturally into the center of these developing chylomicron spheres during assembly. Crucially, the presence of high-purity cannabidiol actively modifies this process, stimulating the cell to up-regulate its output of essential structural proteins, specifically apolipoprotein A1 and apolipoprotein A4.[16] This target protein up-regulation increases the overall velocity of chylomicron production, boosting the transport output of lipids into the alternative intestinal lymphatic system.

Because these chylomicron packages feature a large molecular size, they are physically blocked from entering the tight, continuous junctions of neighboring blood capillaries, moving instead toward the wide, flexible openings of the central lymphatic lacteals located at the center of each intestinal villus.[14] The chylomicrons flow smoothly through these wide gateways, entering the lymphatic fluid to travel upward through the thoracic duct and enter general circulation via the vena cava, completely avoiding the portal vein and first-pass liver clearance. Bypassing hepatic filtration allows the active parent molecules to distribute directly to peripheral target tissues throughout the body, providing a smoother, more sustained release into the systemic bloodstream that helps senior animals maintain comfortable, un-hindered movement throughout the day.[23]

CBD accelerates its own delivery: High-purity cannabidiol up-regulates apolipoprotein A1 and A4 production inside the enterocyte, boosting chylomicron output velocity and increasing the rate of its own lymphatic transport into systemic circulation, bypassing the liver entirely.

Clinical dosage over time crossover chart showing NSAID carprofen reduction from 100 percent at Week 1 to 67 percent at Week 2 to 50 percent at Week 3 as cannabinoid sparing effect becomes active illustrating how full spectrum CBD enables hepatic logjam clearance and carprofen threshold reduction in Great Dane osteoarthritis management

Harnessing the Pharmaceutical-Sparing Effect to Clear the Hepatic Logjam

Diverting the cannabinoid payload down the lymphatic pathway ensures that the active plant compounds can reach peripheral tissue targets at full therapeutic strength, triggering a powerful clinical interaction known as the pharmaceutical-sparing or opioid-sparing effect. When clean, full-spectrum cannabinoids saturate the tissue matrix surrounding an inflamed hip or shoulder joint, they do not act as simple surface coverings; instead, they function as non-competitive allosteric modulators of alternative pain pathways and central nervous system receptors.[7] This multi-tier structural interaction fundamentally changes how the canine nervous system perceives and processes chronic discomfort, altering the shape of target receptor pockets to amplify the body's natural pain-relieving signals.[19]

This cross-system synergy provides an exceptional tool for advanced veterinary care, allowing practitioners to safely reduce the daily required volume of conventional NSAIDs by thirty to fifty percent while maintaining superior joint comfort.[13] By lowering the required daily milligram intake of medications like carprofen, the continuous influx of toxic compounds hitting the liver's CYP2C21 pathway drops significantly, clearing the metabolic bottleneck and allowing the liver cells to recover from chronic exhaustion. This down-regulation provides excellent, multi-tiered pain relief while significantly reducing the long-term risk of pharmaceutical-induced organ strain, helping senior Great Danes stay comfortable without compromising their internal health.

Phytocannabinoid biosynthesis pathway diagram from Berman Futoran Lewitus et al Nature Scientific Reports 2018 showing CBGA cannabigerolic acid conversion to Delta-9-THCA Delta-8-THCA CBDA CBCA CBNA CBTA CBNDA CBEA CBLA types via THCA synthase CBDA synthase CBCA synthase isomerization oxidation and photochemical reaction illustrating carboxylic acid preservation through low-temperature solventless mechanical processing

Preserving Carboxylic Potency through Low-Temperature Mechanical Processing

To achieve this high level of clinical synergy and protect the internal organ systems of a senior giant breed, formulators must avoid heavily processed isolates and utilize extraction techniques that preserve the plant's native chemical structures. The primary goal of advanced processing science is to capture the hemp plant's natural raw carboxylic acids, most notably cannabidiolic acid, which would otherwise be destroyed by industrial thermal processing.[22] Raw cannabidiolic acid acts as an exceptionally potent, highly selective inhibitor of the canine cyclooxygenase-two enzyme, exhibiting a unique physical shape that sets it completely apart from neutral cannabidiol.[18]

Because of the unique physical shape and negative charge distribution of its attached carboxyl group, CBDA fits cleanly into the specific, elongated binding pocket of the inflammatory COX-2 enzyme, locking the structure closed with an exceptionally low inhibitory concentration value. Crucially, the bulky carboxyl group creates a structural shape that cannot fit into the tighter, more rigid binding channel of the protective COX-1 enzyme, meaning that raw CBDA passes right over the stomach's protective systems and the kidney's filtration networks without causing disruption. This high level of selectivity allows raw cannabidiolic acid to deliver powerful, targeted anti-inflammatory relief directly to inflamed joints and irritated nerve endings while safely avoiding the gastrointestinal and renal risks associated with traditional anti-inflammatory drugs.[18]

To capture this delicate raw asset without introducing chemical contaminants or thermal damage, processing must utilize low-temperature mechanical rosin pressing, a solventless separation technique that applies immense physical pressure between dual aluminum plates maintained at a tightly regulated temperature well below the activation threshold of the decarboxylation curve.[17] This low-temperature method squeezes the un-altered cannabinoid matrix out of the plant tissue as a clean oil, naturally retaining the native, co-evolved terpene ratios to ensure the full power of the entourage effect is preserved. Co-evolved compounds like myrcene and beta-caryophyllene act as natural membrane modifiers, lowering the physical resistance of biological barriers and allowing molecules like CBDA to move into target tissues more efficiently, maximizing the structural impact of the dose while minimizing overall liver load.[12]

Split-panel infographic showing morning raw dog food bowl with salmon kale blueberries and butternut squash on blue background beside evening raw dog food bowl with beef beets and herbs on warm tan background with 12 Hour Splitting text overlay illustrating structured cannabinoid ingestion windows timed to meals for maximum chylomicron lymphatic transport in Great Dane osteoarthritis dosing protocol

Clinical Protocol: Structured Ingestion Windows and Twelve-Hour Splitting

Because the desensitization of alternative receptors and the maintenance of lymphatic transport rely on active digestive processes, the timing of the dose relative to the animal's feeding schedule must be carefully controlled. Administering a cannabinoid protocol to a fasting dog limits overall absorption, even when using a high-quality long-chain carrier oil. In a completely empty stomach and small intestine, the baseline production of bile salts and pancreatic lipases is minimal, meaning there are not enough natural digestive juices available to break the carrier oil down into absorbable micelles or trigger the enterocytes to assemble new transport vesicles.[5]

Introducing the dose alongside solid dietary fats triggers a robust release of chylomicrons within the gut wall, maximizing lymphatic transport and ensuring the primary cannabinoid payload is safely guided past liver filtration to provide lasting, systemic relief. To maintain a stable, protective level of compound access without triggering rapid clear-out cycles, this fat co-activation routine must use a split, twelve-hour schedule.[21] Delivering the cannabinoid payload twice daily alongside morning and evening meals ensures that plasma levels remain within a tight, predictable therapeutic window that matches the continuous clearing rate of the canine body. This dual-dose schedule prevents the precipitous drop-off in systemic concentration that occurs when active clearing mechanisms regain total control, allowing senior Great Danes to maintain consistent comfort and regular physical movement throughout the day.

Full Spectrum. Solventless. Batch Verified.

Every VetsGrade product is extracted without solvents and tested by ISO 17025-accredited laboratories. COAs are publicly searchable by Batch ID.

Shop Products Read More

Frequently Asked Questions

Great Danes undergo a hyper-accelerated growth curve during their first eighteen months of life, increasing their birth weight by up to one hundred-fold within this brief window. This rapid growth phase places immense physical stress on the immature skeletal framework, where the development of dense cortical bone often lags behind the animal's rapid mass accumulation. This developmental imbalance frequently leads to structural irregularities like coxofemoral laxity, osteochondritis dissecans, and severe elbow incongruity that create permanent mechanical issues across the articulating joint spaces, accelerating cartilage matrix degradation throughout the animal's adult life.

Yes. Because a Great Dane can weigh between sixty and ninety kilograms, the absolute daily milligram payload required to maintain a therapeutic drug concentration is exceptionally high, forcing the liver's CYP2C21 enzyme networks to operate under maximum, non-stop demand. Over months of uninterrupted high-dose use, this massive chemical influx can hit the liver's saturation threshold, driving the local enzymes into chronic metabolic exhaustion. Active compounds accumulate in the bloodstream, placing measurable physical stress on liver cells reflected in rising serum Alkaline Phosphatase and Alanine Aminotransferase levels. If left unmanaged, this enzymatic overload can progress to acute hepatotoxicity or permanent hepatic lipidosis.

When full-spectrum cannabinoids saturate the tissue matrix surrounding an inflamed hip or shoulder joint, they function as non-competitive allosteric modulators of alternative pain pathways and central nervous system receptors, fundamentally changing how the canine nervous system perceives and processes chronic discomfort. This cross-system synergy allows practitioners to safely reduce the daily required volume of conventional NSAIDs by 30 to 50 percent while maintaining superior joint comfort. By lowering the required daily milligram intake of medications like carprofen, the continuous influx of toxic compounds hitting the liver's CYP2C21 pathway drops significantly, clearing the metabolic bottleneck.

When CBD is delivered within a long-chain triglyceride fat matrix, the enterocytes package the cannabinoids inside chylomicron lipoprotein vesicles that enter the intestinal lymphatic lacteals rather than blood capillaries. The chylomicrons travel through the thoracic duct into systemic circulation, completely bypassing the portal vein and the canine liver's aggressive CYP450 enzyme networks that would otherwise destroy up to 85 percent of the active dose. This alternative path delivers a smoother, more sustained release of active compounds to peripheral target tissues throughout the body.

Raw cannabidiolic acid is the unheated precursor to CBD preserved only in solventless, low-temperature extractions. CBDA fits cleanly into the specific, elongated binding pocket of the inflammatory COX-2 enzyme with an exceptionally low inhibitory concentration value. The bulky carboxyl group creates a structural shape that cannot fit into the tighter, more rigid binding channel of the protective COX-1 enzyme, meaning CBDA passes right over the stomach's protective systems and the kidney's filtration networks without causing disruption. This selectivity delivers powerful anti-inflammatory relief to inflamed joints without the gastrointestinal and renal risks associated with traditional NSAIDs.

In a fasting dog, baseline production of bile salts and pancreatic lipases is minimal, limiting the micellar solubilization and chylomicron synthesis required for optimal cannabinoid absorption. Administering the cannabinoid regimen during or immediately following a meal containing healthy solid fats triggers a robust release of bile and lipase activity, creating a steady stream of chylomicron transport vehicles ready to absorb the lipophilic plant compounds and guide them past liver filtration into systemic circulation.

A single large daily dose creates a sharp plasma spike followed by rapid clearance, leaving the dog unprotected for the remaining hours of the day. Delivering the cannabinoid payload twice daily alongside morning and evening meals maintains plasma levels within a tight, predictable therapeutic window that matches the continuous clearing rate of the canine body, preventing the precipitous drop-off in systemic concentration that occurs when active clearing mechanisms regain total control.

Traditional industrial extraction methods use aggressive chemical solvents that require massive heat applications to purge from the final oil, triggering decarboxylation that converts raw CBDA into neutral CBD and destroying the delicate carboxyl group responsible for COX-2 selectivity. Low-temperature mechanical rosin pressing applies immense physical pressure between aluminum plates maintained well below the activation threshold of the decarboxylation curve, squeezing the un-altered cannabinoid matrix out as a clean oil that retains native CBDA concentrations and co-evolved terpene ratios for the full entourage effect.

References

1 Wakshlag JJ, Schwark WS, Deabold KA, Talsma BN, Cital S, Lyubimov A, Iqbal A, Zakharov A. et al. Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract. Frontiers in Veterinary Science. 2020 Sep 4;7:505. doi: 10.3389/fvets.2020.00505. PMID: 33102539; PMCID: PMC7498943. Frontiers
2 Todhunter R, et al. Gene expression in hip soft tissues in incipient canine hip dysplasia and osteoarthritis. Journal of Orthopedic Research. 2019 Feb;37(2):313-324. doi: 10.1002/jor.24178. Epub 2018 Dec 27. Wiley
3 Doran CE, McGrath S, Bartner LR, Thomas B, Cribb AE, Gustafson DL, et al. Drug-Drug Interaction Between Cannabidiol and Phenobarbital in Healthy Dogs. American Journal of Veterinary Research. 22021 Nov 1;83(1):86-94. doi: 10.2460/ajvr.21.08.0120. PMID: 34727050. AVMA
4 Ewing LE, Skinner CM, Quick CM, Kennon-McGill S, McGill MR, Walker LA, ElSohly MA, Gurley BJ, Koturbash I, et al. Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model. Molecules. 2019 Apr 30;24(9):1694. doi: 10.3390/molecules24091694. PMID: 31052254; PMCID: PMC6539990. MDPI
5 Trevaskis NL, Charman WN, Porter CJ, et al. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Advanced Drug Delivery Reviews. 2008 Mar 17;60(6):702-16. doi: 10.1016/j.addr.2007.09.007. Epub 2007 Nov 7. PMID: 18155316; PMCID: PMC7103284. Science Direct
6 Wright A, Amodie DM, Cernicchiaro N, Lascelles BDX, Pavlock AM, Roberts C, Bartram DJ, et al. Identification of canine osteoarthritis using an owner-reported questionnaire and treatment monitoring using functional mobility tests. Journal of Small Animal Practice. 2022 Aug;63(8):609-618. doi: 10.1111/jsap.13500. Epub 2022 Apr 6. PMID: 35385129; PMCID: PMC9543207. Wiley
7 Kathmann M, et al. Cannabidiol is an Allosteric Modulator at Mu- and Delta-Opioid Receptors. Naunyn-Schmiedeberg's Archives of Pharmacology. 2006 Feb;372(5):354-61. doi: 10.1007/s00210-006-0033-x. Epub 2006 Feb 18. Springer
8 Kok LY, Bannigan P, Sanaee F, Evans JC, Dunne M, Regenold M, Ahmed L, Dubins D, Allen C, et al. Development and pharmacokinetic evaluation of a self-nanoemulsifying drug delivery system for the oral delivery of cannabidiol. Eurpean Journal of Pharmaceutics. 2022 Jan 1;168:106058. doi: 10.1016/j.ejps.2021.106058. Epub 2021 Nov 8. PMID: 34763088. sciencedirect.com
9 Bassalo D, Matthews SG, Bloise E, et al. The canine blood-brain barrier in health and disease: focus on brain protectionl. Veterinary Quaterly. 2025 Dec;45(1):12-32. doi: 10.1080/01652176.2025.2450041. Epub 2025 Jan 10. PMID: 39791202; PMCID: PMC11727060. Veterinary Quaterly
10 McGrath S, et al. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. Journal of the American Veterinary Medical Association. 2019;254(11):101-108. AVMA
11 Trevaskis NL, Charman WN, Porter CJ, et al. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Advanced Drug Delivery Reviews. 2007;59(7):608-621. Science Direct
12 Russo EB. Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects. British Journal of Pharmacology. 2011;163(7):1344-1364. wiley.com
13 Russo EB. The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No "Strain," No Gain. Frontiers in Plant Science. 2019 Jan 9;9:1969. doi: 10.3389/fpls.2018.01969. PMID: 30687364; PMCID: PMC6334252. Frontiers
14 Rysanek D, et al. The Effect of Medium Chain and Long Chain Triglycerides in Lipid-Based Self-Emulsifying Drug Delivery Systems on the Oral Absorption of Major Cannabinoids. International Journal of Pharmaceutics. 2020;109(11):3411-3420. sciencedirect.com
15 Samara E, et al. Pharmacokinetics of Cannabidiol in Dogs. Drug Metabolism and Disposition. 1988;16(3):247-254. dmd.aspetjournals.org
16 Shrestha N, et al. The Impact of Cannabidiol (CBD) on Lipid Absorption and Lymphatic Chylomicron Transport Dynamics. Nutrients. 2025;17(4):2010-2022. mdpi.com
17 Sommano SR, et al. The Cannabis Terpenes: An Assessment of Volatile Organic Compound Profiles Across Variable Extraction Temperatures. Molecules. 2020;25(12):1-11. mdpi.com
18 Takeda S, et al. Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis. Drug Metabolism and Disposition. 2008;36(6):1090-1096. dmd.aspetjournals.org
19 Vasal N, et al. Structure-Activity Relationship Study of Cannabidiol-Based Analogues at the Mu-Opioid Receptor Interface. Journal of Medicinal Chemistry. 2023;66(14):11-24. pubs.acs.org
20 Vanscheeuwijck A, et al. In Vitro Metabolism of Phytocannabinoids and Their Capacity to Inhibit Canine Cytochrome P450 (CYP) Enzymes. Journal of Veterinary Pharmacology and Therapeutics. 2024;47(2):140-149. wiley.com
21 Wakshlag JJ, et al. Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Frontiers in Veterinary Science. 2020;7:1-9. frontiersin.org
22 Wang M, Wang YH, Avula B, Radwan MM, Wanas AS, van Antwerp J, Parcher JF, ElSohly MA, Khan IA, et al. Decarboxylation Study of Acidic Cannabinoids: A Novel Approach Using Ultra-High-Performance Supercritical Fluid Chromatography/Photodiode Array-Mass Spectrometry. Cannabis and Cannabinoid Research. 2016 Dec 1;1(1):262-271. doi: 10.1089/can.2016.0020. PMID: 28861498; PMCID: PMC5549281. NCBI
23 Zgair A, Wong JC, Lee JB, Mistry J, Sivak O, Wasan KM, Hennig IM, Barrett DA, Constantinescu CS, Fischer PM, Gershkovich P, et al. Dietary Fats and Pharmaceutical Lipid Excipients Wrap Cannabinoids for Intestinal Lymphatic Transport. American Journal of Translational Research. 2016 Aug 15;8(8):3448-59. PMID: 27648135; PMCID: PMC5009397. NCBI

Disclaimer: This article is intended for informational and educational purposes only and does not constitute veterinary medical advice, diagnosis, or treatment. The information presented is based on published peer-reviewed research and is not a substitute for professional veterinary consultation. Full spectrum CBD products have not been evaluated by the FDA for the diagnosis, treatment, cure, or prevention of any disease or condition in animals. Individual results may vary. Dogs and cats with preexisting medical conditions or concurrent medications require veterinary supervision before initiating any CBD protocol. CYP450 enzyme inhibition by cannabinoids may alter plasma concentrations of concurrently administered medications. Disclose all supplement use to your veterinarian.